suvorexant Alzheimer insomnia
Selected indexed studies
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. (Ann Neurol, 2023) [PMID:36897120]
- Treatment of Alzheimer Disease. (Continuum (Minneap Minn), 2024) [PMID:39620846]
- Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease. (Annu Rev Pharmacol Toxicol, 2024) [PMID:37708433]
_Worker-drafted node — pending editorial review._
Connections
suvorexant Alzheimer insomnia is a side effect of
Sources
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. (2023) pubmed
- Pharmacotherapies for sleep disturbances in dementia. (2020) pubmed
- Treatment of Alzheimer Disease. (2024) pubmed
- Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease. (2024) pubmed
- Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review. (2021) pubmed
- Suvorexant for Preventing Alzheimer's Disease. (2023) pubmed
- Suvorexant for the treatment of insomnia in patients with Alzheimer's disease. (2018) pubmed
- A Review of Recent Advances in the Management of Alzheimer's Disease. (2024) pubmed
- Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. (2020) pubmed
- Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia. (2022) pubmed